Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)
Recruiting now · Phase 2
Conditions studied: Buruli Ulcer
In brief
The goal of this interventional clinical trial is to demonstrate the complete BU lesion healing rate by 52 weeks after treatment initiation, without relapse and/or curative intent excision surgery, after 10-28 days of telacebec (T) treatment. Males and females age 18 and older will be included. • Participants will attend visits every 2 weeks during treatment and thereafter every 2 weeks until week 24 Thereafter they will be followed by visits at weeks 30, 40, and 52. From week 10 to week 52, if the lesion has healed, follow-up visits may be remote.
Key facts
- Study ID
- NCT06481163
- Run by
- Barwon Health
- People needed
- 200
- Starts
- 2024-07-09
- Expected to finish
- 2028-01-01
- Last updated by the study team
- 2026-06-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Barwon Health — Geelong, Victoria, Australia (enrolling)
- Royal Melbourne Hospital — Melbourne, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.